GLORIA

GEOMAR Library Ocean Research Information Access

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Amsterdam : Elsevier
    Journal of Chromatography B: Biomedical Sciences and Applications 228 (1982), S. 409-412 
    ISSN: 0378-4347
    Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 43 (2000), S. 321-322 
    ISSN: 1437-1588
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 43 (2000), S. 323-327 
    ISSN: 1437-1588
    Keywords: Schlüsselwörter Umwelt und Gesundheit ; Aktionsprogramm ; Umweltmedizin ; Risikomanagement gesundheitsbezogene Umweltqualitätsziele ; Keywords Environment and Health ; Action Programme ; Environmental Medicine ; Risk Management ; Health Related Environmental Quality Objectives
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Abstract In fulfilling the commitment to the European Conferences on Environmental Health the Federal Ministry for Health and the Federal Ministry for the Environment, Nature Conservation and Nuclear Safety presented a joint “Action Programme on Environment and Health”. The action programme is backed up by a comprehensive documentation presenting the current status and findings and providing justification for the proposed goals and measures. The programme covers the following subjects: environment health monitoring and reporting, information management, risk perception and risk acceptance, environmental medicine, measures to improve co-operation among competent national authorities, international co-operation. The programme also conveys media- and substance-oriented quality objectives, in particular concerning outdoor air and climate; indoor air; water resources, soil, food; ionising radiation; noise; substances and preparations. The programme is aimed at supporting the policy development in the field of environment and health. The planing of detailed steps and the programme's implementation will be performed in close co-ordination and co-operation of all parties interested/involved and afflicted/affected.
    Notes: Zusammenfassung Das gemeinsame Aktionsprogramm “Umwelt und Gesundheit” des Ministeriums für Gesundheit und des Ministeriums für Umwelt, Naturschutz und Reaktorsicherheit löst die eingegangene Verpflichtung ein, die aus den europäischen Umweltkonferenzen resultiert. Das Programm dient dem Ziel, eine Handlungsbasis aufzustellen, auf welcher der Gesundheitszustand der Bürger und Bürgerinnen in Bereichen sichergestellt wird, die durch ungünstige Einflüsse von Umweltnoxen physikalischer Natur, mediengetragenen Umweltnoxen oder durch Aufnahme beim Umgang mit Verbraucherprodukten des täglichen Bedarfs oder durch die Nahrung gefährdet sein können. Das Programm wurde auf dem Hintergrund eines ausführlichen Dokumentationsbandes erstellt, der den aktuellen Sach- und Erkenntnisstand ausführlich darstellt und damit die vorgeschlagenen Ziele und Maßnahmen inhaltlich begründet. Das Programm enthält folgende Themen: umweltbezogene Gesundheitsbeobachtung und -berichterstattung, Informationsmanagement, Umgang mit Risiken, Umweltmedizin, Verbesserung der bestehenden Behördenstrukturen und internationale Zusammenarbeit. Das Programm enthält zudem verschiedene medien- und stoffbezogene Qualitätsziele zu folgenden Themen: Außenluft und Klima; Innenraumluft; Wasserressourcen, Boden, Lebensmittel, ionisierende Strahlung; Lärm sowie Stoffe und Zubereitungen. Das Programm soll eine Arbeitsgrundlage für die weitere Entwicklung des Politikfeldes Umwelt und Gesundheit bilden. Die weitere Ausgestaltung um Umsetzung des Programms wird in intensivem Diskurs mit allen Beteiligten und Betroffenen erfolgen.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1437-1588
    Keywords: Schlüsselwörter Vergiftungen ; Humandaten ; Monitorsystem ; Toxikovigilanz ; Keywords Poisonings ; Human Data ; Monitoring system ; Toxicovigilance
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary From 1st August 1990 onwards health complaints in connection with chemical product exposure were assessed by an official monitoring system. The reports of the primary care physicians are documented in a standardized form, assessed, evaluated and analysed. Results are reparted and recommendations for risk management are directed to the published. Beside the systematic documentation of human toxicological data in form of standard files and case-reports, the monitoring system has an important toxicovigilance function: Serious health effects from acute or chromic chemical product exposure are analysed immediately, all other health complaints from exposures annually and directed for risk-management to the producers, distributors, industrial associations and the government.
    Notes: Zusammenfassung Seit 1.8.1990 werden gesundheitliche Störungen im Zusammenhang mit chemischen Produkten mit Hilfe eines gesetzlichen Monitorsystems erfasst. Die Mitteilungen der behandelnden Ärzte werden standardisiert dokumentiert, bewertet und analysiert. Die Ergebnisse werden regelmäßig veröffentlicht. Neben der systematischen Dokumentation von toxikologischen Daten am Menschen durch Standarddatensätze und Einzelkasuistiken, hat das Monitorsystem eine besondere Leistungsfähigkeit durch eine Risikoidentifizierungs-/Toxikovigilanz-Funktion: Schwerwiegende Beeinträchtigungen der Gesundheit werden unmittelbar, alle übrigen einmal im Jahr analysiert und den Ministerien, Herstellern, Vertreibern und den Industrieverbänden zum Risikomanagement mitgeteilt-
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 69 (1991), S. 796-796 
    ISSN: 1432-1440
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1432-1912
    Keywords: µ-, δ-, κ-Opioid-Receptor ; Morphine ; Morphine-3-O-β-D-Glucuronide ; Morphine-6-O-β-D-Glucuronide ; Cerebral membranes ; In-vitro-binding
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We investigated the nature of interaction of morphine-3-O-β-D-glucuronide (M3G) and morphine6-O-β-D-glucuronide (M6G) with opioid binding sites at the µ-, δ- and κ-opioid receptors (µ-OR, δ-OR and κ-OR) in cerebral membranes. Saturation binding experiments revealed a competitive interaction of M6G with all three opioid receptors. Inhibition binding experiments at the µ-OR employing combinations of morphine and M6G resulted in a rightward shift of the IC50 for morphine proportional to the M6G concentration, thus strengthening the finding of competitive interaction of M6G at the µ-opioid binding site. Data in absence and presence of M6G were included in a three-dimensional model. Compared to a model with one binding site a model with two binding sites significantly improved the fits. This might indicate that different µ-OR subtypes are involved. Hydrolysis of M6G to morphine was investigated and did not occur. Therefore the effects of M6G on binding to the μ-OR were due to M6G and not due to morphine. In contrast, M3G at the three opioid receptors was found to inhibit binding being about 300 times weaker than morphine. This effect was well explained by the amount of contaminating morphine (about 0.3%) identified by HPLC. We conclude that M6G binds to µ-, δ- and κ-OR in a competitive manner. Some of our results on the µ-OR suggest two binding sites for agonists at the μ-OR and that M6G binds to both sites. Our results suggest that the high potency of M6G as an analgesic is mediated through opioid receptors. In contrast, M3G does not interact with the µ-, δ- or κ-OR. We therefore doubt that any effect of M3G is mediated via opioid receptors.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    ISSN: 1432-1971
    Keywords: Key words: Amiodarone — Intracardiac tumor — Ventricular tachycardia — Computer-assisted dose finding
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. We report the successful management of recurrent ventricular tachycardias in a newborn suffering from an intracardiac tumor. Amiodarone was the only agent able to control the tachycardias and did so as long as an individually titrated plasma concentration above 0.8 μmol/L was maintained. Because no therapeutic plasma concentration has been defined in children and no kinetic studies are available in this population, we optimized the dosing regimen based on a computer simulation, taking into account the pharmacokinetic parameters of the patient and the individual concentration–effect relation.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    ISSN: 1432-1912
    Keywords: Key words μ- ; δ- ; κ-Opioid-Receptor ; Morphine ; Morphine-3-O-β-D-Glucuronide ; Morphine-6-O-β-D-Glucuronide ; Cerebral membranes ; In-vitro-binding
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  We investigated the nature of interaction of morphine-3-O-β-D-glucuronide (M3G) and morphine-6-O-β-D-glucuronide (M6G) with opioid binding sites at the μ-, δ- and κ-opioid receptors (μ-OR, δ-OR and κ-OR) in cerebral membranes. Saturation binding experiments revealed a competitive interaction of M6G with all three opioid receptors. Inhibition binding experiments at the μ-OR employing combinations of morphine and M6G resulted in a rightward shift of the IC50 for morphine proportional to the M6G concentration, thus strengthening the finding of competitive interaction of M6G at the μ-opioid binding site. Data in absence and presence of M6G were included in a three-dimensional model. Compared to a model with one binding site a model with two binding sites significantly improved the fits. This might indicate that different μ-OR subtypes are involved. Hydrolysis of M6G to morphine was investigated and did not occur. Therefore the effects of M6G on binding to the μ-OR were due to M6G and not due to morphine. In contrast, M3G at the three opioid receptors was found to inhibit binding being about 300 times weaker than morphine. This effect was well explained by the amount of contaminating morphine (about 0.3%) identified by HPLC. We conclude that M6G binds to μ-, δ- and κ-OR in a competitive manner. Some of our results on the μ-OR suggest two binding sites for agonists at the μ-OR and that M6G binds to both sites. Our results suggest that the high potency of M6G as an analgesic is mediated through opioid receptors. In contrast, M3G does not interact with the μ-, δ- or κ-OR. We therefore doubt that any effect of M3G is mediated via opioid receptors.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 52 (1997), S. 387-390 
    ISSN: 1432-1041
    Keywords: Key words CYP2D6 ; Fluoxetine ; Maprotiline; CYP2C19 ; CYP3A4 ; CYP1A2 ; antide-pressant therapy ; ultra-rapid metaboliser
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract Case: We are reporting about a patient with major depression who failed to respond to pharmacotherapy due to ultra-rapid metabolism of maprotiline. Under daily oral doses of 175 mg maprotiline, the patient's metabolic ratio (MR) for maprotiline in plasma was 9.2 (expected MRp: 2.4) and the clearance of maprotiline (CLM) was 4190 ml · min−1 (expected CLM = 1220 in extensive metabolisers of CYP2D6). Results: The patient's MRurine for sparteine was 0.5, which is within the range for extensive metabolisers of CYP2D6. Genotyping did not show a duplication of the CYP2D6L allele. The patient's caffeine half-life was 10 h, thus, precluding ultra-rapid metabolism for CYP1A2. The therapeutic regimen was changed to coadministration of 200 mg maprotiline and 20 mg fluoxetine once per day in order to inhibit metabolism via CYP2D6. Subsequently, MRp of maprotiline (4.9) and CLM were reduced (1900 ml · min−1; expected CLM in poor metabolisers: of CYP2D6 364). This regimen improved the clinical outcome of the underlying disease. Conclusion: We conclude that for the non-response seen with maprotiline, P450 isozymes other than CYP2D6 or CYP1A2 are responsible. As CYP2C19 is involved in the metabolism of a number of tricyclic antidepressants it may be a candidate for ultra-rapid metabolism in this patient.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    ISSN: 1432-1041
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Abstract Objective: The pharmacokinetics and pharma-codynamics of the angiotensin (AT) II receptor, AT1-subtype, antagonist candesartan were investigated in a dose-finding study in 232 patients of either gender, aged 28–69 years and weighing 54–110 kg. The study was a double-blind, placebo-controlled trial in which oral doses of 2, 4, 8, 12 and 16 mg once daily were given as the pro-drug candesartan cilexetil from day 0 to day 28. Results: The population pharmacokinetics of candesartan could be best described by a two-compartment body model, parameterized in terms of clearance (14.1 l · h−1), central volume of distribution (118 l), peripheral volume (272 l) and intercompartmental clearance (15.4 l · h−1). From these model parameters, a cumulation half-life (t1/2,β) of 29 h was derived. Age and weight were influencing factors for the distribution and elimination of the drug. Systolic and diastolic blood pressure were lowered by the treatment in a dose-dependent fashion. The maximum effect of each dose was reached after repeated administration. The link between plasma concentrations and effect could be described by a linear model when trough concentrations and blood pressure, measured at the same time, were modelled. In this model, the time dependence is implicitly handled as the trough concentrations increased during repeated administration. After treatment with the highest dose used in the trial (16 mg), the population estimate for the diastolic blood pressure was reduced from 103.2 mmHg (pre-dose day 0) to 93.3 mmHg (on day 29) and the systolic blood pressure from 154.6 mmHg (pre-dose day 0) to 137.9 mmHg (on day 29). None of the covariates (age, weight, gender) had an influence on the concentration–effect relationship.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...